LAWRENCE SCHERRER, MD PHD
Dermatology at Craig Rd, Eau Claire, WI
License number
Wisconsin 39932
Category
Osteopathic Medicine
Type
Dermatology
Address
Address
2
2116 Craig Rd, Eau Claire, WI 54701
1000 N Oak Ave, Marshfield, WI 54449
1000 N Oak Ave, Marshfield, WI 54449
Phone
(715) 858-4747
Organization information
See more information about LAWRENCE SCHERRER at bizstanding.comLawrence Scherrer MD
2116 Craig Rd, Eau Claire, WI 54701
Industry:
Medical Doctor's Office, Dermatologist
Doing business as:
Lawrence Scherrer MD,PHD
Phone:
(715) 858-4500 (Phone)
Description:
There are 55 doctors at this site. Surgery is not performed at this site.
Medical Doctor, Principal:
Lawrence Scherrer (Medical Doctor, Principal)
Professional information
Lawrence Clark Scherrer, Eau Claire WI
Specialties:
Dermatology
Work:
Marshfield Clinic Eau Claire Center
2116 Craig Rd, Eau Claire, WI 54701
2116 Craig Rd, Eau Claire, WI 54701
Education:
University of Minnesota, Twin Cities (1994)
Dr. Lawrence Scherrer, Eau Claire WI - MD (Doctor of Medicine)
Specialties:
Dermatology
Address:
Marshfield Clinic Eau Claire
2116 Craig Rd, Eau Claire 54701
(715) 858-4500 (Phone)
2116 Craig Rd, Eau Claire 54701
(715) 858-4500 (Phone)
Certifications:
Dermatology, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Marshfield Clinic Eau Claire
2116 Craig Rd, Eau Claire 54701
Sacred Heart Hospital
401 West Mohawk Dr, Tomahawk 54487
2116 Craig Rd, Eau Claire 54701
Sacred Heart Hospital
401 West Mohawk Dr, Tomahawk 54487
Education:
Medical School
University of Mn Med Sch
Graduated: 1992
University of Mn Med Sch
Graduated: 1992
Method Of Inhibiting Growth Of Neoplastic Cells And Inhibiting Infection By Administering An Immune Enhancer Drug
US Patent:
8211906, Jul 3, 2012
Filed:
Aug 4, 2004
Appl. No.:
10/912009
Inventors:
Lawrence C. Scherrer - Eau Claire WI, US
International Classification:
A01N 43/42, A01N 43/52
US Classification:
514290, 514393
Abstract:
Disclosed is a method of inhibiting the growth of neoplastic tumors and lesions and localized infections by administering an Immune Response Modifier (IRM) drug to human patients suffering from such tumors, lesions or infections. IRMs act by stimulating cellular immunity and have been found to have both anti-viral and anti-tumor effects. By administering IRM drugs directly into a tumor, lesion or infection, the cells of the tumor, lesion or infection, as well as those surrounding the tumor, lesion or infection can be stimulated to increase their cellular response, thereby inhibiting the growth of such tumors, lesions or infections.